Posted by Michael Wonder on 17 Feb 2022
Lupin announces FDA approval of supplemental new drug application for Solosec (secnidazole) in adolescents for both the treatment of bacterial vaginosis in females and trichomoniasis
17 February 2022 - Lupin Pharmaceuticals today announced that the U.S. FDA has approved the company's supplemental new drug application to expand the use of Solosec (secnidazole) in the treatment of bacterial vaginosis for female patients 12 years of age and older and in the treatment of trichomoniasis for all patients 12 years of age and older.
The supplemental adolescent approval enhances Solosec's strong position as the first and only single-dose oral prescription antimicrobial agent approved for the treatment of both trichomoniasis and bacterial vaginosis.
